$62 Million Cancer Vaccine Research Collaboration Launches at Oxford

GSK plc and the University of Oxford (Oxford) today announced that they have entered a new research collaboration focused on the potential of cancer prevention through vaccination.
GSK will invest up to £50 million ($62m) over three years to support this early research.
Confirmed on January 27, 2025, the GSK-Oxford Cancer Immuno-Prevention Programme will conduct translational research, exploring precancer biology to generate key insights on how cancer develops in humans that could inform new approaches to cancer vaccination.
Professor Irene Tracey, Vice-Chancellor of the University of Oxford, commented in a press release, “This partnership represents a step forward in cancer research. By working with GSK to unite experts in clinical trials, immuno-oncology, vaccinology, and precancer research from across the University of Oxford, we aim to unlock the potential of cancer vaccines and bring hope to patients worldwide.”
Our Trust Standards: Medical Advisory Committee